Showing results (271-280 of 277) with videos related to
Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 277 results.
Cancer Biology & Medicine|March 2, 2023
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphomaPing Li, Yang Liu, Yun Liang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.Journal for Immunotherapy of Cancer|October 25, 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, et al.International Journal of Hematology|July 24, 2021
Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in AsiaYong-Pyo Lee, Sang Eun Yoon, Yuqin Song, et al.The Lancet Regional Health. Western Pacific|July 30, 2021
Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in AsiaSang Eun Yoon, Yuqin Song, Seok Jin Kim, et al.Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.Advances in Therapy|March 22, 2021
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Hui Zhou, Huilai Zhang, et al.Pageof 28